Founded by Stephen C. Glover, ZyVersa Therapeutics is a clinical-stage specialty biopharmaceutical company built around licensed technologies from University of Miami Miller School of Medicine researchers. The company develops medicines for patients with serious inflammatory and renal diseases, with its work centered on unmet medical needs rather than established treatments.
Lazarus Pharmaceuticals, LLCLazarus Pharmaceuticals is a clinical-stage drug development company that identifies and advances therapies for diseases with unmet medical needs. Its two gastroenterology portfolio companies are pursuing treatments for functional gastrointestinal disease and a rare neonatal GI condition. Co-founders Alan Joslyn and Joseph Sanger bring decades of pharmaceutical development and commercial experience to the company’s asset-focused model.LANGHORNE, PA
Calliditas Therapeutics ABFounded in Sweden in 2004 as Pharmalink AB, Calliditas Therapeutics develops and commercializes medicines for rare diseases, with an initial focus on kidney and liver disorders. The company pioneered the first treatment specifically designed for IgA nephropathy and markets TARPEYO in the United States, while partners commercialize related therapies in other regions.New York, NY
Tactical TherapeuticsFounded in 2005 by cancer scientist and patent attorney Rashida A. Karmali, Tactical Therapeutics is a clinical-stage biopharmaceutical company built around her long career in cancer research, drug development, and intellectual property law. The company develops CTO, an oral therapy designed to reach the brain, for patients with glioblastoma and other cancers that have resisted treatment. Karmali has authored more than 100 scientific publications and holds eight U.S. patents alongside more than 75 international patents.NEW YORK, NY
Rapafusyn PharmaceuticalsEmerging from Johns Hopkins professor Jun O. Liu’s laboratory, Rapafusyn Pharmaceuticals develops non-degrading molecular-glue medicines designed to reach hard-to-drug intracellular and transmembrane targets. Based on its RapaGlue™ platform, the Baltimore biotech is advancing an early pipeline that includes an ENT1 inhibitor for acute kidney injury, an area where the company says no approved preventive therapies exist. Its discovery engine combines AI-enabled machine learning with a DNA-encoded library containing more than 8 billion non-degrading glues.BALTIMORE, MD